PharmAust (ASX:PAA) has signed agreements with Veterinary Specialists Auckland and Intuit Regulatory to expand its canine Phase 2b lymphoma studies into New Zealand.
The company said the expansion is in preparation for its Phase 3 trial that is anticipated to commence in May 2022.
The company announced it has signed an agreement with Dr Mike Coleman DVM and Dr Tommy Fluen DVM. Both are fellows of the Australian and New Zealand College of Veterinary Scientists and both are registered specialists in small animal internal medicine.
They both work at Veterinary Specialists Auckland and can accept dog lymphoma referrals in New Zealand’s North Island.
Regulatory and ethical compliance is overseen by Dr Julia McNab PhD of Intuit Regulatory who has specialist expertise in Phase 3 design and registration.
Dr Tommy Fluen said, “We look forward to working with PharmAust and trial Principal Investigator Dr Kim Agnew to test the hypothesis that monepantel will provide a well-tolerated oral therapy for canines with lymphoma, which is superior to steroids alone and without the costs and risks of chemotherapy.”
Principal Investigator Dr Kim Agnew said, “It is always very beneficial for any product development building towards a Phase 3 study to expand knowledge in new market settings so having the NZ team combine with our team is very good for the PharmAust program.”
PharmAust’s chief scientific officer Dr Richard Mollard added, “PharmAust is delighted to work with Dr Coleman, Dr Fluen and Dr McNab to establish a clinical trial site in New Zealand. Establishing trial procedures, structures and systems with these groups and receiving their feedback will provide great value to PharmAust in preparing for Phase 3 and potentially later with product roll-out.”